Stockscreener 앱 받기
4.16
5.85%
0.23
전일 마감가:
$3.93
열려 있는:
$3.92
하루 거래량:
732.45K
Relative Volume:
1.11
시가총액:
$245.15M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
79.39
EPS:
0.0524
순현금흐름:
$12.42M
1주 성능:
+5.32%
1개월 성능:
-4.81%
6개월 성능:
-16.80%
1년 성능:
-25.45%
1일 변동 폭
$3.89
$4.2395
1주일 범위
$3.8092
$4.2395
52주 변동 폭
$3.8092
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.16 | 232.79M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Sets Key Investor Meetings at Major Neuro & Ophthalmology Conference Next Week - Stock Titan
Mystics tap D.C.'s Vanda Pharmaceuticals as new jersey sponsor - The Business Journals
Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics - Monumental Sports
Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Can - GuruFocus
Vanda Pharmaceuticals (VNDA) Projected to Transform with Overwei - GuruFocus
Vanda Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald - TipRanks
Vanda Receives Positive CHMP Opinion for HETLIOZ® (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union | Libero Quotidiano.it - Libero Quotidiano
Vanda pharmaceuticals outlines $210M-$250M revenue target for 2025 amid product launches - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges - TipRanks
Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Vanda: Q1 Earnings Snapshot - MySA
Vanda Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats - GuruFocus
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2025 forecasts - Investing.com
Capitals Announce Game 3 Watch Party at The Wharf as Part of Additional Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com
Vanda Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.50 Beats Estimate, Revenue Surpasses Forecast at $50 Million - GuruFocus
Vanda Pharmaceuticals (VNDA) Reports Strong Q1 Revenue and Expands Product Pipeline | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results - StreetInsider
HC Wainwright & Co. Reiterates Buy Rating on Vanda Pharmaceutica - GuruFocus
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial R - GuruFocus
A Glimpse of Vanda Pharma's Earnings Potential - Nasdaq
3 Penny Stocks Under $300M Market Cap To Consider - simplywall.st
Vanda Pharmaceuticals Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Drugmaker Vanda Announces Bysanti NDA Filing - marketscreener.com
FDA Begins Review Process on Vanda Pharmaceuticals' (VNDA) Drug - GuruFocus
FDA accepts Vanda’s new antipsychotic drug for review By Investing.com - Investing.com India
FDA accepts Vanda’s new antipsychotic drug for review - Investing.com
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 | VNDA Stock News - GuruFocus
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 - PR Newswire
FDA Sets 2026 Decision Date for Vanda's New Mental Health Drug with 20+ Year Patent Life - Stock Titan
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - The Malaysian Reserve
Press Release Distribution & PR Platform - ACCESS Newswire
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Earnings Alert: Key Q1 2025 Financial Results Drop May 7 After Market Close - Stock Titan
Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
FDA’s job cuts paint mixed picture for drugmakers’ R&D plans - Yahoo Finance
Halozyme sues Merck; FDA blames cuts for Vanda delay - BioPharma Dive
FDA delays Vanda Pharmaceuticals drug hearing By Investing.com - Investing.com India
FDA delays Vanda Pharmaceuticals drug hearing - Investing.com Australia
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Vanda Pharmaceuticals Inc 주식 (VNDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 05 '25 |
Buy |
5.02 |
10,000 |
50,200 |
2,285,731 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 03 '25 |
Buy |
4.71 |
10,000 |
47,050 |
2,275,731 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 28 '25 |
Buy |
4.76 |
10,000 |
47,600 |
2,361,730 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 27 '25 |
Buy |
4.76 |
10,000 |
47,600 |
2,351,730 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 26 '25 |
Buy |
4.76 |
10,000 |
47,650 |
2,341,730 |
| Polymeropoulos Mihael Hristos | President and CEO |
Feb 25 '25 |
Buy |
4.46 |
10,000 |
44,640 |
2,331,730 |
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Feb 21 '25 |
Buy |
4.39 |
2,000 |
8,779 |
355,763 |
| Mitchell Stephen Ray | Director |
Nov 14 '24 |
Sale |
5.17 |
5,000 |
25,863 |
44,857 |
1.54%
7.58%
자본화:
|
볼륨(24시간):